| Name | cyclopentyl-[[3,4-di(tetradecoxy)phenyl]methyl]-dimethylazanium,iodide |
|---|---|
| Synonyms |
Benzenemethanaminium, N-cyclopentyl-N,N-dimethyl-3,4-bis(tetradecyloxy)-, iodide (1:1)
N-[3,4-Bis(tetradecyloxy)benzyl]-N,N-dimethylcyclopentanaminium iodide |
| Description | CAY10614 is a potent TLR4 antagonist. CAY10614 inhibits the lipid A-induced activation of TLR4, with an IC50 of 1.675 μM. CAY10614 can improve survival of mice in lethal endotoxin shock model[1][2]. |
|---|---|
| Related Catalog | |
| Target |
TLR4:1.675 μM (IC50, in HEK293 cells) |
| In Vitro | CAY10614 (compound 7) (1-10 μM) inhibits the lipid A-induced increase of phosphatase activity in a concentration-dependent manner in HEK293 cells[1]. CAY10614 (0.5 μM) inhibits the increase of [Ca2+]cyt induced by LPS in >18 days in vitro (DIV) neurons[2]. |
| In Vivo | CAY10614 (compound 7) (10 mg/kg; i.p. 30 min before the LPS) significantly improves survival of mice given intraperitoneal LPS (20 mg/kg)[1]. Animal Model: C57BL/6J male mice (9 weeks) were i.p. injected with 20 mg/kg LPS[1] Dosage: 10 mg/kg Administration: I.p. 30 min before the LPS Result: Increased the survival rate of mice from 0% to 67%. |
| References |
| Molecular Formula | C42H78INO2 |
|---|---|
| Molecular Weight | 755.979 |
| Exact Mass | 755.507690 |
| PSA | 18.46000 |
| LogP | 10.36940 |